Cell Therapy in Dilated Cardiomyopathy: Observational Study

Cell Therapy in Dilated Cardiomyopathy: A Safety and Feasibility Study Using Autologous Bone Marrow Mononuclear Cells

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00612911

Enrollment

Registered

2008-02-12

Start date

2005-02-28

Completion date

2007-08-31

Last updated

2008-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathy, Dilated

Brief summary

Using bone marrow mononuclear cell in 24 patients with Idiopathic dilated cardiomyopathy

Detailed description

Patients with Idiopathic dilated cardiomyopathy class II to IV NYHA with ejection fraction \<35% were selected for phase I clinical trial of bone marrow mononuclear cell delivery in the coronary arteries and followed for 6 months

Interventions

OTHERCell therapy

bone marrow mononuclear cell

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of idiopathic dilated cardiomyopathy * Optimized therapy and for idiopathic dilated cardiomyopathy * Left ventricular ejection fraction (Simpson) \< 35% * Peak oxygen consumption (VO2 peak) \< 16 mL.kg-1min-1 * Functional classes II-IV of the NYHA

Exclusion criteria

* dilated cardiopathies of ischemic or chagasic origin * primary valve disease * excessive use of alcohol or illicit drugs * pregnancy * ventricular arrhythmias * any co-morbidity with impact on survival

Design outcomes

Primary

Measure	Time frame
echocardiography	2 months

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026